Welcome to our dedicated page for OpGen news (Ticker: $OPGN), a resource for investors and traders seeking the latest updates and insights on OpGen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OpGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OpGen's position in the market.
OpGen, Inc. announced the sale of its commercial customer contracts and Unyvero systems to Camtech Pte for $218,000. Additionally, Ares Genetics GmbH sold its assets to bioMerieux S.A. OpGen plans to work with Camtech and Curetis team to transfer U.S. Unyvero customers. OpGen also offered Camtech the opportunity to acquire its remaining inventory for $176,000. OpGen's CEO sees these transactions as preparation for potential strategic transactions like a reverse merger.
